August 12, 2019 | Vensana Capital® Events

Vensana Capital Co-Organizes 26th Annual Phoenix Conference

22

Novel FDA PMA & de novo 510k approvals

61

U.S. Commercial Product Launches

40

Level I Clinical Trials

34

Strategic Financings

32

Exits by IPO or M&A